Verrica Pharmaceuticals to Participate in the Jefferies Global Healthcare Conference in New York

Rhea-AI Summary

Verrica Pharmaceuticals (NASDAQ: VRCA), a dermatology therapeutics company, announced its participation in the upcoming Jefferies Global Healthcare Conference in New York City. The company's President and CEO, Jayson Rieger, PhD, MBA, will deliver a presentation on Wednesday, June 4, 2025, at 4:20 pm ET.

The event will be accessible via live webcast through the company's website and a dedicated link. A replay will be available for 90 days following the presentation in the Investors/Presentations & Events section of www.verrica.com.

WEST CHESTER, Pa., May 28, 2025 (GLOBE NEWSWIRE) -- Verrica Pharmaceuticals Inc. (“Verrica” or “the Company”) (Nasdaq: VRCA), a dermatology therapeutics company developing medications for skin diseases requiring medical interventions, today announced that Jayson Rieger, PhD, MBA, President and Chief Executive Officer of Verrica Pharmaceuticals, will present at the Jefferies Global Healthcare Conference in New York City.

Jefferies Global Healthcare Conference, June 3-5, 2025
Event details:
Date: Wednesday, June 4, 2025
Time: 4:20 pm ET
Location: New York, New York

Participants may access a live webcast of the event by clicking the link here.

The webcast can also be accessed in the Investors/Presentations & Events section of the Verrica website at www.verrica.com. A replay of the webcast will be posted shortly after the presentation and will be available for 90 days following the event.

About Verrica Pharmaceuticals Inc. 
Verrica is a dermatology therapeutics company developing medications for skin diseases requiring medical interventions. Verrica’s product YCANTH® (VP-102) (cantharidin), is the first and only commercially available treatment approved by the FDA to treat adult and pediatric patients two years of age and older with molluscum contagiosum, a highly contagious viral skin infection affecting approximately 6 million people in the United States, primarily children. YCANTH® (VP-102) is also in development to treat common warts, the largest remaining unmet need in medical dermatology. Verrica has also entered a worldwide license agreement with Lytix Biopharma AS to develop and commercialize VP-315 (formerly LTX-315 and VP-LTX-315) for non-melanoma skin cancers including basal cell carcinoma and squamous cell carcinoma. For more information, visit www.verrica.com.

FOR MORE INFORMATION, PLEASE CONTACT:
Investors:

John J Kirby 
Interim Chief Financial Officer 
jkirby@verrica.com

Kevin Gardner 
LifeSci Advisors 
kgardner@lifesciadvisors.com

FAQ

When is Verrica Pharmaceuticals (VRCA) presenting at the Jefferies Global Healthcare Conference 2025?

Verrica Pharmaceuticals (VRCA) will present at the Jefferies Global Healthcare Conference on Wednesday, June 4, 2025, at 4:20 pm ET in New York City.

Who will represent Verrica Pharmaceuticals (VRCA) at the Jefferies Healthcare Conference 2025?

Jayson Rieger, PhD, MBA, President and Chief Executive Officer of Verrica Pharmaceuticals, will represent the company at the conference.

How can investors access Verrica Pharmaceuticals' (VRCA) presentation at the Jefferies Conference?

Investors can access the live webcast through a dedicated link or the Investors/Presentations & Events section of Verrica's website at www.verrica.com. A replay will be available for 90 days after the event.

What is Verrica Pharmaceuticals' (VRCA) main business focus?

Verrica Pharmaceuticals is a dermatology therapeutics company that develops medications for skin diseases requiring medical interventions.